The purpose of this proposal is to establish a Clinical Investigator Training Program (CITP) at the Fox Chase Cancer Center. The program is designed for medical, surgical and radiation oncology fellows and residents, respectively, who have completed formal training programs in their disciplines, and who are committed to clinical research. The overall goal of the program is to provide highly focused, individualized training to prepare investigators for careers in which advances in biotechnology, molecular biology, and related disciplines can be integrated into well-designed clinical trials. The program is organized along scientific program lines including: tumor biology, developmental therapeutics, immunobiology and immunotherapy, and radiobiology/radiotherapy to encourage interdisciplinary interactions. Within these sub-groups mentors accomplished in clinically relevant laboratory investigations will shepherd trainees through a two year laboratory-based program with a clinical trial component. This program will be overseen by both a coordinator for each general area, and an advisory committee composed of the scientific leadership of the Medical Science Division. A flexible hands-on practicum ranging from two to six months is provided for all candidates with required rotations in Biostatistics and on the Clinical Research Unit prior to initiating the focused research experience with a designated mentor. This structured exposure will acquaint trainees with critical concepts and techniques which are relevant to their proposed research. An extensive didactic exposure to clinical research methodology, lectures relating to molecular biology, epidemiology, pharmacology, and biostatistics is provided as well. Scheduled monitoring of the candidate's progress is provided by the mentor, coordinator and advisory committee throughout the two year period of training. At the conclusion of two years, promising, productive trainees will have the option for yearly competitive renewals for an additional two years to facilitate their transition into independent investigators.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Physician Scientist Award (Program) (PSA) (K12)
Project #
Application #
Study Section
Special Emphasis Panel (SRC (72))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fox Chase Cancer Center
United States
Zip Code
Cohen, Steven J; Alpaugh, R Katherine; Gross, Steve et al. (2006) Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 6:125-32
Sundermeyer, Mark L; Meropol, Neal J; Rogatko, Andre et al. (2005) Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 5:108-13
Lewis, N L; Mullaney, M; Mangan, K F et al. (2004) Measurable immune dysfunction and telomere attrition in long-term allogeneic transplant recipients. Bone Marrow Transplant 33:71-8
Cohen, Steven J; Gallo, James; Lewis, Nancy L et al. (2004) Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer. Cancer Chemother Pharmacol 53:513-8
Cohen, Steven J; Ho, Linus; Ranganathan, Sulabha et al. (2003) Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 21:1301-6
Cheng, Jonathan D; Dunbrack Jr, Roland L; Valianou, Matthildi et al. (2002) Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res 62:4767-72
von Mehren, M; Arlen, P; Gulley, J et al. (2001) The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 7:1181-91
von Mehren, M; Arlen, P; Tsang, K Y et al. (2000) Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 6:2219-28
Siegelmann-Danieli, N; Buetow, K H (1999) Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer 79:456-63
Siegelmann-Danieli, N; Hanlon, A; Ridge, J A et al. (1998) Oral tongue cancer in patients less than 45 years old: institutional experience and comparison with older patients. J Clin Oncol 16:745-53

Showing the most recent 10 out of 14 publications